{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":10,"sponsored":0,"items":[{"id":"n_iyyvbtawzlzkdmvuje3a","seq":1707241,"kind":"article","title":"Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?","url":"https://www.fool.com/coverage/better-buy/2026/10/04/amgen-vs-vertex-pharmaceuticals-which-biotech-stock-is-a-better-buy-in-2026?source=iedfolrf0000001","published":"2026-10-04T14:14:00Z","seen":"2026-10-04T18:09:18Z","lang":"en","source":{"id":"fool.com","name":"fool.com","domain":"fool.com","outlet":{"wikidata":"Q7752442","name":"The Motley Fool","type":"other","country":"US","designations":["dot-com company"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","politics"],"authors":["Sara Appino"],"entities":[{"id":"Q470517","name":"Amgen","type":"org"},{"id":"Q2744099","name":"Vertex Pharmaceuticals","type":"org"}],"story":"st_iyyvbtawzlzkdmvuje3a","category":"economy-business","category_p":0.68,"sentiment":"neutral","tone":0.01,"political":0.02},{"id":"n_y5sdvboh7ailtuusg5wa","seq":1529663,"kind":"article","title":"Amgen (NASDAQ:AMGN) Shares Purchased by Rep. David Taylor","url":"https://www.themarketsdaily.com/2026/10/03/amgen-nasdaqamgn-shares-purchased-by-rep-david-taylor.html","published":"2026-10-03T12:24:13Z","seen":"2026-10-03T12:24:13Z","lang":"en","source":{"id":"themarketsdaily.com","name":"themarketsdaily.com","domain":"themarketsdaily.com"},"via":"gdelt-gkg-english","topics":["education","economy","politics","business"],"authors":["Kim Johansen"],"entities":[{"id":"Q470517","name":"Amgen","type":"org"},{"id":"Q55762444","name":"David Taylor","type":"person"}],"story":"st_vvtmmudztru5emolcheq","category":"politics","category_p":0.67,"category2":"economy-business","sentiment":"neutral","tone":0.13,"political":0.77},{"id":"n_vvtmmudztru5emolcheq","seq":1508093,"kind":"article","title":"Rep. David Taylor Buys Shares of Amgen Inc. (NASDAQ:AMGN)","url":"https://www.tickerreport.com/banking-finance/13607639/rep-david-taylor-buys-shares-of-amgen-inc-nasdaqamgn.html","published":"2026-10-03T09:22:12Z","seen":"2026-10-03T09:22:12Z","lang":"en","source":{"id":"tickerreport.com","name":"tickerreport.com","domain":"tickerreport.com"},"via":"gdelt-gkg-english","topics":["economy","health","politics","education"],"authors":["Logan Wallace"],"entities":[{"id":"Q55762444","name":"David Taylor","type":"person"},{"id":"Q470517","name":"Amgen","type":"org"}],"story":"st_vvtmmudztru5emolcheq","category":"politics","category_p":0.54,"category2":"economy-business","sentiment":"neutral","tone":0.08,"political":0.65},{"id":"n_ny6uvkab6u5gornpwztq","seq":1331513,"kind":"article","title":"The biotech process development associate in Amgen's grad programme","url":"https://www.siliconrepublic.com/people/biotech-process-development-associate-amgen-graduate-programme","published":"2026-10-02T11:00:00Z","seen":"2026-10-02T11:39:19Z","lang":"en","source":{"id":"siliconrepublic.com","name":"siliconrepublic.com","domain":"siliconrepublic.com","outlet":{"wikidata":"Q62615175","name":"Silicon Republic","type":"website","country":"IE","designations":["business","website"]}},"via":"gdelt-gkg-english","authors":["silicon"],"entities":[{"id":"Q470517","name":"Amgen","type":"org"}],"story":"st_ny6uvkab6u5gornpwztq","category":"science-technology","category_p":0.64,"sentiment":"neutral","tone":0.37,"political":0.04},{"id":"n_suxqihahgll7eriqcazq","seq":874491,"kind":"article","title":"Amgen reveals 6-point drop in lupus severity behind ph. 2 win","url":"https://www.fiercebiotech.com/biotech/amgen-reveals-6-point-drop-lupus-severity-behind-phase-2-win-horizon-antibody","published":"2026-09-30T09:56:40Z","seen":"2026-09-30T09:56:40Z","lang":"en","source":{"id":"fiercebiotech.com","name":"fiercebiotech.com","domain":"fiercebiotech.com"},"via":"gdelt-gkg-english","topics":["economy","politics","health"],"entities":[{"id":"Q470517","name":"Amgen","type":"org"},{"id":"Q10571","name":"Lupus","type":"other"}],"story":"st_suxqihahgll7eriqcazq","category":"health","category_p":0.57,"sentiment":"positive","tone":-0.09,"political":0.02},{"id":"n_aytunaw574byq3sfrjiq","seq":681812,"kind":"article","title":"Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead","url":"https://www.aol.com/articles/why-amgen-6-dividend-raise-130317000.html","published":"2026-09-29T13:03:00Z","seen":"2026-09-29T13:40:32Z","lang":"en","source":{"id":"aol.com","name":"aol.com","domain":"aol.com","outlet":{"wikidata":"Q27585","name":"AOL","type":"website","country":"US","designations":["business","company","enterprise","media company","online service provider","search engine","web portal"]}},"via":"gdelt-gkg-english","topics":["business","economy","health","disaster"],"authors":["AOL"],"entities":[{"id":"Q470517","name":"Amgen","type":"org"}],"story":"st_aytunaw574byq3sfrjiq","category":"economy-business","category_p":0.9,"sentiment":"negative","tone":-0.18,"political":0.24},{"id":"n_2r47lzu653j7ahv3cdqa","seq":638991,"kind":"article","title":"エイプリルバイオ、アムジェン出身者迎える","title_en":"April Bio welcomes Amgen alumni","url":"https://www.chosun.com/jp/economy-jp/2026/09/29/Y4T5XLMOXNGHNJAPX4DXF7N6AM","summary":"エイプリルバイオは29日、海外製薬会社出身のファン・ソンジン副社長を迎え入れたと発表した。同社は新薬開発を拡大し、海外事業を強化する計画だ。ファン副社長はソウル峨山病院、サムスンソウル病院で勤務した医師出身だ。米メルク、ギリアド・サイエンシズ、アムジェンなどと韓国企業で20年間勤務した。新薬開発戦略の策定から臨床、海外プロジェクト管理、規制当局関連業務の経験が","published":"2026-09-29T10:04:34Z","seen":"2026-09-29T10:16:22Z","lang":"ko","country":"KR","source":{"id":"kite-chosun-com-8d8927","name":"chosun.com","domain":"chosun.com","outlet":{"wikidata":"Q483924","name":"The Chosun Ilbo","type":"newspaper","country":"KR","designations":["newspaper"]}},"via":"kite-chosun-com-8d8927","authors":["홍다영 기자(조선비즈)"],"entities":[{"id":"Q470517","name":"Amgen","type":"org"}],"image":"https://www.chosun.com/resizer/v2/MEYTEYRTMQ4WEMJRGNSTON3EGE.jpg?auth=d011d838cf84c54393749ecb6413f9f4099165c5699c1d82d3311631c49f3e24&height=1204&smart=true&width=860","story":"st_2r47lzu653j7ahv3cdqa","category":"arts-culture-entertainment","category_p":0.33,"category2":"science-technology","sentiment":"neutral","tone":0.34,"political":0.03},{"id":"n_r3yn3lum7mvwtv52xukq","seq":638990,"kind":"article","title":"에이프릴바이오, 암젠 출신 황선진 부사장 영입","title_en":"April Bio hires former Amgen executive Hwang Sun-jin as vice president","url":"https://www.chosun.com/economy/science/2026/09/29/MZTDONLCMRRDKOBTHBTDSZTCGY","summary":"에이프릴바이오는 해외 제약사 출신 황선진 부사장을 영입했다고 29일 밝혔다. 회사는 신약 개발을 확대하고 해외 사업을 강화할 계획이다. 황 부사장은 서울아산병원, 삼성서울병원에서 근무한 의사 출신이다. 미국 머크, 길리어드 사이언스, 암젠 등과 국내 기업에서 20년간 근무했다. 신약 개발 전략 수립부터 임상, 해외 프로젝트 관리, 규제기관 관련 업무 경험이","published":"2026-09-29T10:04:34Z","seen":"2026-09-29T10:16:22Z","lang":"ko","country":"KR","source":{"id":"kite-chosun-com-8d8927","name":"chosun.com","domain":"chosun.com","outlet":{"wikidata":"Q483924","name":"The Chosun Ilbo","type":"newspaper","country":"KR","designations":["newspaper"]}},"via":"kite-chosun-com-8d8927","authors":["홍다영 기자(조선비즈)"],"entities":[{"id":"Q470517","name":"Amgen","type":"org"}],"image":"https://www.chosun.com/resizer/v2/MEYTEYRTMQ4WEMJRGNSTON3EGE.jpg?auth=d011d838cf84c54393749ecb6413f9f4099165c5699c1d82d3311631c49f3e24&height=1204&smart=true&width=860","story":"st_guqs72ppv4jslqkff3ha","category":"economy-business","category_p":0.65,"sentiment":"neutral","tone":0.19,"political":0.05},{"id":"n_juxi7polni3eej2ufotq","seq":307892,"kind":"article","title":"Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back","url":"https://www.insidermonkey.com/news/amgen-amgn-sells-its-deerfield-campus-for-151-million-and-leases-it-back-1844917","published":"2026-09-27T22:21:40Z","seen":"2026-09-27T22:21:40Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","business"],"authors":["Suraj Santlani"],"entities":[{"id":"Q470517","name":"Amgen","type":"org"},{"id":"Q375905","name":"Deerfield","type":"place"}],"story":"st_juxi7polni3eej2ufotq","category":"economy-business","category_p":0.86,"sentiment":"positive","tone":0.0,"political":0.01},{"id":"n_iefslfoa5mprgdn73bgq","seq":307765,"kind":"article","title":"Why Amgen's Pipeline Just Got More Interesting","url":"https://www.insidermonkey.com/news/why-amgens-pipeline-just-got-more-interesting-1845163","published":"2026-09-27T22:21:40Z","seen":"2026-09-27T22:21:40Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"authors":["Vardah Gill"],"entities":[{"id":"Q470517","name":"Amgen","type":"org"}],"story":"st_iefslfoa5mprgdn73bgq","category":"economy-business","category_p":0.67,"sentiment":"positive","tone":0.15,"political":0.11}]}